Antimicrobial Agents and Chemotherapy · 1993 · 26 citations · 7 references
Life SciencesInfectious DiseasesMicrobiologyAntimicrobial ResistanceBacteriologyMedical MicrobiologyAntibacterial PharmacologyAntibiotic ResistanceAntimicrobial Susceptibility TestingBacterial InfectionsResistance In Gram-negative BacteriaResistance In Gram-positive BacteriaAnaerobic Soft Tissue InfectionsAntibiotic Resistance In Respiratory PathogensBacterial Respiratory InfectionEscherichia ColiLegionella InfectionPseudomonas Aeruginosa ResistanceRespiratory Bacterial Infections TreatmentStreptococcus Species
BAY Y3118 was highly active against Moraxella catarrhalis, Haemophilus influenzae, Legionella pneumophila, Escherichia coli, Klebsiella pneumoniae, Staphylococcus aureus (except quinolone-resistant, methicillin-resistant S. aureus), Staphylococcus epidermidis, Streptococcus pyogenes, Streptococcus agalactiae, and Streptococcus pneumoniae (MIC for 90% of strains tested [MIC90], 0.063 micrograms/ml). For Enterococcus faecalis and Corynebacterium jeikeium, MIC90s were 4 and 2 micrograms/ml, respectively. BAY Y3118 was as active as ciprofloxacin against Pseudomonas aeruginosa (MIC90, 0.5 micrograms/ml) and had potent activity against Bacteroides fragilis (MIC90, 0.5 micrograms/ml).
7
Atsushi Saitô, Katsuhiko Sawatari, Yusuke Fukuda et al. · Antimicrobial Agents and Chemotherapy · 1985 · 99 citations · Full text